Treatment for pulmonary hypertension of left heart disease

Marco Guazzi, Alessandra Vitelli, Valentina Labate, Ross Arena

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Pulmonary hypertension (PH) secondary to left heart disease is a largely underestimated target of therapy. Except for a specific focus on PH consequences in patients with advanced heart failure (HF) receiving a left ventricular mechanical assist device or candidates for transplantation, prevention and treatment of initial subclinical forms of PH are not considered a priority in the management of this chronic disease population. Nonetheless, there is recent growing evidence supporting a clinical and prognostic role of PH in the elderly and in HF with preserved ejection fraction (pEF). Studies have defined PH-HFpEF as a new entity typically defining the evolving nature of disease. Although the prevalence of PH in these populations is not well-defined, the potential for effective pharmacological approaches that might impact the natural history of the disease starting from earlier stages is promising. However, it should be recognized that pharmacological studies performed to date with traditional pulmonary vasodilators in cohorts with HF and left-sided PH have not been positive, primarily because of concomitant systemic hypotension and hepatic side effects. This evidence along with the lack of studies specifically performed in the elderly and HFpEF often lead Guidelines to give neutral recommendations or even arbitrary assumptions. Recent availability of selective well-tolerated pulmonary vasodilators, such as phosphodiesterase type 5 (PDE5) inhibitors, however, seem to offer a solid background for treating left-sided PH at both early and later stages of the disease process.

Original languageEnglish
Pages (from-to)319-327
Number of pages9
JournalCurrent Treatment Options in Cardiovascular Medicine
Volume14
Issue number4
DOIs
Publication statusPublished - Aug 2012

Fingerprint

Pulmonary Hypertension
Heart Diseases
Heart Failure
Therapeutics
Vasodilator Agents
Pharmacology
Phosphodiesterase 5 Inhibitors
Lung
Heart-Assist Devices
Hypotension
Population
Chronic Disease
Transplantation
Guidelines
Liver

Keywords

  • Cardiac resynchronization therapy
  • Endothelin-1 receptor blockers
  • Heart failure
  • LV assist devices
  • Nitric oxide
  • PDE-5 inhibitors
  • Prostaglandins
  • Pulmonary hypertension
  • Pulmonary vasodilators

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Treatment for pulmonary hypertension of left heart disease. / Guazzi, Marco; Vitelli, Alessandra; Labate, Valentina; Arena, Ross.

In: Current Treatment Options in Cardiovascular Medicine, Vol. 14, No. 4, 08.2012, p. 319-327.

Research output: Contribution to journalArticle

Guazzi, Marco ; Vitelli, Alessandra ; Labate, Valentina ; Arena, Ross. / Treatment for pulmonary hypertension of left heart disease. In: Current Treatment Options in Cardiovascular Medicine. 2012 ; Vol. 14, No. 4. pp. 319-327.
@article{62be08656e70485bb0b022d31654187a,
title = "Treatment for pulmonary hypertension of left heart disease",
abstract = "Pulmonary hypertension (PH) secondary to left heart disease is a largely underestimated target of therapy. Except for a specific focus on PH consequences in patients with advanced heart failure (HF) receiving a left ventricular mechanical assist device or candidates for transplantation, prevention and treatment of initial subclinical forms of PH are not considered a priority in the management of this chronic disease population. Nonetheless, there is recent growing evidence supporting a clinical and prognostic role of PH in the elderly and in HF with preserved ejection fraction (pEF). Studies have defined PH-HFpEF as a new entity typically defining the evolving nature of disease. Although the prevalence of PH in these populations is not well-defined, the potential for effective pharmacological approaches that might impact the natural history of the disease starting from earlier stages is promising. However, it should be recognized that pharmacological studies performed to date with traditional pulmonary vasodilators in cohorts with HF and left-sided PH have not been positive, primarily because of concomitant systemic hypotension and hepatic side effects. This evidence along with the lack of studies specifically performed in the elderly and HFpEF often lead Guidelines to give neutral recommendations or even arbitrary assumptions. Recent availability of selective well-tolerated pulmonary vasodilators, such as phosphodiesterase type 5 (PDE5) inhibitors, however, seem to offer a solid background for treating left-sided PH at both early and later stages of the disease process.",
keywords = "Cardiac resynchronization therapy, Endothelin-1 receptor blockers, Heart failure, LV assist devices, Nitric oxide, PDE-5 inhibitors, Prostaglandins, Pulmonary hypertension, Pulmonary vasodilators",
author = "Marco Guazzi and Alessandra Vitelli and Valentina Labate and Ross Arena",
year = "2012",
month = "8",
doi = "10.1007/s11936-012-0185-6",
language = "English",
volume = "14",
pages = "319--327",
journal = "Current Treatment Options in Cardiovascular Medicine",
issn = "1092-8464",
publisher = "Current Science, Inc.",
number = "4",

}

TY - JOUR

T1 - Treatment for pulmonary hypertension of left heart disease

AU - Guazzi, Marco

AU - Vitelli, Alessandra

AU - Labate, Valentina

AU - Arena, Ross

PY - 2012/8

Y1 - 2012/8

N2 - Pulmonary hypertension (PH) secondary to left heart disease is a largely underestimated target of therapy. Except for a specific focus on PH consequences in patients with advanced heart failure (HF) receiving a left ventricular mechanical assist device or candidates for transplantation, prevention and treatment of initial subclinical forms of PH are not considered a priority in the management of this chronic disease population. Nonetheless, there is recent growing evidence supporting a clinical and prognostic role of PH in the elderly and in HF with preserved ejection fraction (pEF). Studies have defined PH-HFpEF as a new entity typically defining the evolving nature of disease. Although the prevalence of PH in these populations is not well-defined, the potential for effective pharmacological approaches that might impact the natural history of the disease starting from earlier stages is promising. However, it should be recognized that pharmacological studies performed to date with traditional pulmonary vasodilators in cohorts with HF and left-sided PH have not been positive, primarily because of concomitant systemic hypotension and hepatic side effects. This evidence along with the lack of studies specifically performed in the elderly and HFpEF often lead Guidelines to give neutral recommendations or even arbitrary assumptions. Recent availability of selective well-tolerated pulmonary vasodilators, such as phosphodiesterase type 5 (PDE5) inhibitors, however, seem to offer a solid background for treating left-sided PH at both early and later stages of the disease process.

AB - Pulmonary hypertension (PH) secondary to left heart disease is a largely underestimated target of therapy. Except for a specific focus on PH consequences in patients with advanced heart failure (HF) receiving a left ventricular mechanical assist device or candidates for transplantation, prevention and treatment of initial subclinical forms of PH are not considered a priority in the management of this chronic disease population. Nonetheless, there is recent growing evidence supporting a clinical and prognostic role of PH in the elderly and in HF with preserved ejection fraction (pEF). Studies have defined PH-HFpEF as a new entity typically defining the evolving nature of disease. Although the prevalence of PH in these populations is not well-defined, the potential for effective pharmacological approaches that might impact the natural history of the disease starting from earlier stages is promising. However, it should be recognized that pharmacological studies performed to date with traditional pulmonary vasodilators in cohorts with HF and left-sided PH have not been positive, primarily because of concomitant systemic hypotension and hepatic side effects. This evidence along with the lack of studies specifically performed in the elderly and HFpEF often lead Guidelines to give neutral recommendations or even arbitrary assumptions. Recent availability of selective well-tolerated pulmonary vasodilators, such as phosphodiesterase type 5 (PDE5) inhibitors, however, seem to offer a solid background for treating left-sided PH at both early and later stages of the disease process.

KW - Cardiac resynchronization therapy

KW - Endothelin-1 receptor blockers

KW - Heart failure

KW - LV assist devices

KW - Nitric oxide

KW - PDE-5 inhibitors

KW - Prostaglandins

KW - Pulmonary hypertension

KW - Pulmonary vasodilators

UR - http://www.scopus.com/inward/record.url?scp=84865695741&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865695741&partnerID=8YFLogxK

U2 - 10.1007/s11936-012-0185-6

DO - 10.1007/s11936-012-0185-6

M3 - Article

VL - 14

SP - 319

EP - 327

JO - Current Treatment Options in Cardiovascular Medicine

JF - Current Treatment Options in Cardiovascular Medicine

SN - 1092-8464

IS - 4

ER -